Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes.
Grancini V, Gramegna A, Zazzeron L, Alicandro G, Porcaro LL, Piedepalumbo F, Lanfranchi C, Daccò V, Orsi E, Blasi F. Grancini V, et al. Among authors: porcaro ll. Diabetes Metab. 2023 Sep;49(5):101466. doi: 10.1016/j.diabet.2023.101466. Epub 2023 Aug 1. Diabetes Metab. 2023. PMID: 37536552
The Language of Diabetes.
Porcaro L. Porcaro L. Home Healthc Now. 2024 Mar-Apr 01;42(2):110-111. doi: 10.1097/NHH.0000000000001254. Epub 2024 Mar 4. Home Healthc Now. 2024. PMID: 38437045 No abstract available.
Effects of insulin therapy optimization with sensor augmented pumps on glycemic control and body composition in people with cystic fibrosis-related diabetes.
Grancini V, Alicandro G, Porcaro LL, Zazzeron L, Gramegna A, Morlacchi LC, Rossetti V, Gaglio A, Resi V, Daccò V, Blasi F, Orsi E. Grancini V, et al. Among authors: porcaro ll. Front Endocrinol (Lausanne). 2023 Aug 31;14:1228153. doi: 10.3389/fendo.2023.1228153. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37720540 Free PMC article. Clinical Trial.
Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulators.
Colombo C, Ramm GA, Lindblad A, Corti F, Porcaro L, Alghisi F, Asherova I, Evans H, Kashirskaya N, Kondratyeva E, Lewindon PJ, de Monestrol I, Oliver M, Ooi CY, Padoan R, Shankar S, Alicandro G. Colombo C, et al. Among authors: porcaro l. J Cyst Fibros. 2023 Mar;22(2):263-265. doi: 10.1016/j.jcf.2023.01.012. Epub 2023 Feb 2. J Cyst Fibros. 2023. PMID: 36739240
39 results